Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbHEuropean News
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter,...
Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
Drug Discovery Research through Collaboration Among 3 Academia Members and 3 Pharmaceutical Companies
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
Two Additional Licenses Granted; Upfront Payment of US$18 Million; Total Potential Transaction Value of up to US$484.7 Million
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
Tokyo, Basking Ridge, NJ, and New York - (April 4, 2018) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and DarwinHealth today...
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
Tokyo, Basking Ridge, NJ, and Los Angeles, Calif., Dec. 12, 2017 –Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology,...
Data at SABCS and ASH Demonstrate Daiichi Sankyo Commitment to Advancing Science in Breast and Blood Cancer
- Updated DS-8201 data in HER2-positive metastatic breast cancer as well as HER2 low-expressing breast cancer to be highlighted at SABCS
-...
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing
Tokyo, Japan, Basking Ridge, NJ, and Berlin, Germany - (October 30, 2017) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope...
Commencement of Collaborative Research on Measurement of Exosomes in Blood from Cancer Patients
Tokyo, Japan (October 16, 2017) - The National Cancer Center Japan (hereafter, National Cancer Center), JVCKENWOOD Corporation (hereafter,...
Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library
Three Japanese pharmaceutical companies collaborate in facilitating drug discovery in Japan through open innovation sharing of compounds developed by...
Daiichi Sankyo Announces TaNeDS Global 2018 Collaborative Drug Discovery Program
Tokyo, Japan (September 26, 2017) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced details of the application for its Ta...
More Stories
